Turmeric as cure-cumin: Promises, problems, and solutions

Dietary Modulation of Cell Signaling Pathways

Volumn , Issue , 2008, Pages 91-135

  Shishodia, Shishir ^a   Misra, Krishna ^b   Aggarwal, Bharat B ^c  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b UNIVERSITY OF ALLAHABAD   (India)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993533667     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (168)

1. Rao DS, Sekhara NC, Satyanarayana MN, and Srinivasan M, Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutr 100(11): 1307-15, 1970.
2. Patil TN and Srinivasan M, Hypocholesteremic effect of curcumin in induced hypercholesteremic rats. Indian J Exp Biol 9(2): 167-9, 1971.
3. Keshavarz K, The influence of turmeric and curcumin on cholesterol concentration of eggs and tissues. Poult Sci 55(3): 1077-83, 1976.
4. Soudamini KK, Unnikrishnan MC, Soni KB, and Kuttan R, Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J Physiol Pharmacol 36(4): 239-43, 1992.
5. Soni KB and Kuttan R, Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36(4): 273-5, 1992.
6. Hussain MS and Chandrasekhara N, Effect on curcumin on cholesterol gall-stone induction in mice. Indian J Med Res 96: 288-91, 1992.
7. Asai A and Miyazawa T, Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 131(11): 2932-5, 2001.
8. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E, and Gil A, Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147(2): 371-8, 1999.
9. Naidu KA and Thippeswamy NB, Inhibition of human low density lipoprotein oxidation by active principles from spices. Mol Cell Biochem 229(1-2): 19-23, 2002.
10. Patro BS, Rele S, Chintalwar GJ, Chattopadhyay S, Adhikari S, and Mukherjee T, Protective activities of some phenolic 1,3-diketones against lipid peroxidation: possible involvement of the 1,3-diketone moiety. Chembiochem 3(4): 364-70, 2002.
11. Srivastava R, Puri V, Srimal RC, and Dhawan BN, Effect of curcumin on platelet aggregation and vascular prostacyclin synthesis. Arzneimittelforschung 36(4): 715-7, 1986.
12. Srivastava KC, Bordia A, and Verma SK, Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 52(4): 223-7, 1995.
13. Srivastava R, Dikshit M, Srimal RC, and Dhawan BN, Anti-thrombotic effect of curcumin. Thromb Res 40(3): 413-7, 1985.
14. Dikshit M, Rastogi L, Shukla R, and Srimal RC, Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. Indian J Med Res 101: 31-5, 1995.
15. Nirmala C and Puvanakrishnan R, Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159(2): 85-93, 1996.
16. Nirmala C and Puvanakrishnan R, Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. Biochem Pharmacol 51(1): 47-51, 1996.
17. Venkatesan N, Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124(3): 425-7, 1998.
18. Srinivasan M, Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26(4): 269-70, 1972.
19. Babu PS and Srinivasan K, Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 152(1): 13-21, 1995.
20. Babu PS and Srinivasan K, Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Mol Cell Biochem 166(1-2): 169-75, 1997.
21. Suresh Babu P and Srinivasan K, Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 181(1-2): 87-96, 1998.
22. Arun N and Nalini N, Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 57(1): 41-52, 2002.
23. Deodhar SD, Sethi R, and Srimal RC, Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71: 632-4, 1980.
24. Natarajan C and Bright JJ, Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168(12): 6506-13, 2002.
25. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, and Cole GM, The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21(21): 8370-7, 2001.
26. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, and Cole GM, Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22(6): 993-1005, 2001.
27. Sui Z, Salto R, Li J, Craik C, and Ortiz de Montellano PR, Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem 1(6): 415-22, 1993.
28. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, and Pardee AB, Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA 90(5): 1839-42, 1993.
29. Jordan WC and Drew CR, Curcumin-a natural herb with anti-HIV activity. J Natl Med Assoc 88(6): 333, 1996.
30. Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E, and Pommier Y, Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 40(19): 3057-63, 1997.
31. Barthelemy S, Vergnes L, Moynier M, Guyot D, Labidalle S, and Bahraoui E, Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res Virol 149(1): 43-52, 1998.
32. Sidhu GS, Singh AK, Thaloor D, Banaudha KK, Patnaik GK, Srimal RC, and Maheshwari RK, Enhancement of wound healing by curcumin in animals. Wound Repair Regen 6(2): 167-77, 1998.
33. Phan TT, See P, Lee ST, and Chan SY, Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing. J Trauma 51(5): 927-31, 2001.
34. Shahed AR, Jones E, and Shoskes D, Quercetin and curcumin up-regulate antioxidant gene expression in rat kidney after ureteral obstruction or ischemia/reperfusion injury. Transplant Proc 33(6): 2988, 2001.
35. Morikawa T, Matsuda H, Ninomiya K, and Yoshikawa M, Medicinal foodstuffs. XXIX. Potent protective effects of sesquiterpenes and curcumin from Zedoariae Rhizoma on liver injury induced by D-galactosamine/lipopolysaccharide or tumor necrosis factor-alpha. Biol Pharm Bull 25(5): 627-31, 2002.
36. Awasthi S, Srivatava SK, Piper JT, Singhal SS, Chaubey M, and Awasthi YC, Curcumin protects against 4-hydroxy-2-trans-nonenal-induced cataract formation in rat lenses. Am J Clin Nutr 64(5): 761-6, 1996.
37. Venkatesan N and Chandrakasan G, Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant. Mol Cell Biochem 142(1): 79-87, 1995.
38. Venkatesan N, Punithavathi V, and Chandrakasan G, Curcumin protects bleomycin- induced lung injury in rats. Life Sci 61(6): PL51-8, 1997.
39. Venkatesan N, Pulmonary protective effects of curcumin against paraquat toxicity. Life Sci 66(2): PL21-8, 2000.
40. Punithavathi D, Venkatesan N, and Babu M, Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 131(2): 169-72, 2000.
41. Saleheen D, Ali SA, Ashfaq K, Siddiqui AA, Agha A, and Yasinzai MM, Latent activity of curcumin against leishmaniasis in vitro. Biol Pharm Bull 25(3): 386-9, 2002.
42. Gomes Dde C, Alegrio LV, de Lima ME, Leon LL, and Araujo CA, Synthetic derivatives of curcumin and their activity against Leishmania amazonensis. Arzneimittelforschung 52(2): 120-4, 2002.
43. Koide T, Nose M, Ogihara Y, Yabu Y, and Ohta N, Leishmanicidal effect of curcumin in vitro. Biol Pharm Bull 25(1): 131-3, 2002.
44. Huang HC, Jan TR, and Yeh SF, Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 221(2-3): 381-4, 1992.
45. Chen HW and Huang HC, Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 124(6): 1029-40, 1998.
46. Vogel MM and Pelletier, Journ de Pharm 2: 50, 1815.
47. Daube FW, Uber Curcumin, den Farbstoff der Curcumawurzel. Ber Dtsch Chem Ges 3: 609-13, 1870.
48. Ammon HP and Wahl MA, Pharmacology of Curcuma longa. Planta Med 57(1): 1-7, 1991.
49. Khopde SM, Priyadarsini KI, Venkatesan N, and Rao MNA, Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophysical Chemistry 80(2): 83-89, 1999.
50. Aggarwal BB, Kumar A, and Bharti AC, Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A): 363-98, 2003.
51. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP, and Shoji M, EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16(3): 263-75, 2005.
52. Kuo ML, Huang TS, and Lin JK, Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1317(2): 95-100, 1996.
53. Ranjan D, Johnston TD, Reddy KS, Wu G, Bondada S, and Chen C, Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. J Surg Res 87(1): 1-5, 1999.
54. Piwocka K, Zablocki K, Wieckowski MR, Skierski J, Feiga I, Szopa J, Drela N, Wojtczak L, and Sikora E, A novel apoptosis-like pathway, independent of mitochondria and caspases, induced by curcumin in human lymphoblastoid T (Jurkat) cells. Exp Cell Res 249(2): 299-307, 1999.
55. Han SS, Chung ST, Robertson DA, Ranjan D, and Bondada S, Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 93(2): 152-61, 1999.
56. Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B, and Brasitus TA, 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. J Biol Chem 274(50): 35505-13, 1999.
57. Korutla L and Kumar R, Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1224(3): 597-600, 1994.
58. Aggarwal S, Takada Y, Singh S, Myers JN, and Aggarwal BB, Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111(5): 679-92, 2004.
59. Bharti AC, Donato N, and Aggarwal BB, Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171(7): 3863-71, 2003.
60. Shishodia S, Amin HM, Lai R, and Aggarwal BB, Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70(5): 700-13, 2005.
61. Mehta K, Pantazis P, McQueen T, and Aggarwal BB, Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8(5): 470-81, 1997.
62. Ramachandran C and You W, Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res Treat 54(3): 269-78, 1999.
63. Simon A, Allais DP, Duroux JL, Basly JP, Durand-Fontanier S, and Delage C, Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 129(1): 111-6, 1998.
64. Fang J, Lu J and Holmgren A, Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280(26): 25284-90, 2005.
65. Kang J, Chen J, Shi Y, Jia J, and Zhang Y, Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem Pharmacol 69(8): 1205-13, 2005.
66. Prusty BK and Das BC, Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer 113(6): 951-60, 2005.
67. Sen S, Sharma H, and Singh N, Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331(4): 1245-52, 2005.
68. Koo JY, Kim HJ, Jung KO, and Park KY, Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 7(2): 117-21, 2004.
69. Holy J, Curcumin inhibits cell motility and alters microfilament organization and function in prostate cancer cells. Cell Motil Cytoskeleton 58(4): 253-68, 2004.
70. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, and Aggarwal BB, Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8): 3175-84, 2004.
71. Mahady GB, Pendland SL, Yun G, and Lu ZZ, Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 22(6C): 4179-81, 2002.
72. Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT, and Yang PC, Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol 65(1): 99-110, 2004.
73. Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, Chung HC, and Kwon HJ, Microarraybased analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res 93(12): 1378-85, 2002.
74. Kuttan R, Bhanumathy P, Nirmala K, and George MC, Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29(2): 197-202, 1985.
75. Busquets S, Carbo N, Almendro V, Quiles MT, Lopez-Soriano FJ, and Argiles JM, Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 167(1): 33-8, 2001.
76. Menon LG, Kuttan R, and Kuttan G, Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 95(1-2): 221-5, 1995.
77. Dorai T, Cao YC, Dorai B, Buttyan R, and Katz AE, Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47(4): 293-303, 2001.
78. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, and Reddy BS, Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59(3): 597-601, 1999.
79. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, and Gescher AJ, Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11(6): 535-40, 2002.
80. Odot J, Albert P, Carlier A, Tarpin M, Devy J, and Madoulet C, In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111(3): 381-7, 2004.
81. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, and Price JE, Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11(20): 7490-8, 2005.
82. Hussain MS and Chandrasekhara N, Biliary proteins from hepatic bile of rats fed curcumin or capsaicin inhibit cholesterol crystal nucleation in supersaturated model bile. Indian J Biochem Biophys 31(5): 407-12, 1994.
83. Heng MC, Song MK, Harker J, and Heng MK, Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143(5): 937-49, 2000.
84. Tourkina E, Gooz P, Oates JC, Ludwicka-Bradley A, Silver RM, and Hoffman S, Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol 31(1): 28-35, 2004.
85. Phan TT, Sun L, Bay BH, Chan SY, and Lee ST, Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring. J Trauma 54(6): 1212-24, 2003.
86. Liacini A, Sylvester J, Li WQ, and Zafarullah M, Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21(3): 251-62, 2002.
87. Verbeek R, van Tol EA, and van Noort JM, Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. Biochem Pharmacol 70(2): 220-8, 2005.
88. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, and Cole GM, Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7): 5892-901, 2005.
89. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, and Das PK, Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139(2): 209-18, 2003.
90. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gomez-Munoz A, and Jacobson K, Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285(1): G235-43, 2003.
91. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, and Caplan MJ, Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304(5670): 600-2, 2004.
92. Berger AL, Randak CO, Ostedgaard LS, Karp PH, Vermeer DW, and Welsh MJ, Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl-channel activity. J Biol Chem 280(7): 5221-6, 2005.
93. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905): 707-12, 1989.
94. Korutla L, Cheung JY, Mendelsohn J, and Kumar R, Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16(8): 1741-5, 1995.
95. Hong RL, Spohn WH, and Hung MC, Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5(7): 1884-91, 1999.
96. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, and Rhim JS, Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 21(4): 825-30, 2002.
97. Xu J, Fu Y and Chen A, Activation of peroxisome proliferator-activated receptorgamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 285(1): G20-30, 2003.
98. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, and Howells L, Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18(44): 6013-20, 1999.
99. Chen H, Zhang ZS, Zhang YL, and Zhou DY, Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 19(5A): 3675-80, 1999.
100. Chun KS, Keum YS, Han SS, Song YS, Kim SH, and Surh YJ, Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 24(9): 1515-24, 2003.
101. Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, and Sharma RA, Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 10(12): 1295-9, 2001.
102. Reddy S and Aggarwal BB, Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 341(1): 19-22, 1994.
103. Liu JY, Lin SJ, and Lin JK, Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14(5): 857-61, 1993.
104. Hasmeda M and Polya GM, Inhibition of cyclic AMP-dependent protein kinase by curcumin. Phytochemistry 42(3): 599-605, 1996.
105. Ohene-Abuakwa Y, Noda M, Perenyi M, Kobayashi N, Kashima K, Hattori T, and Pignatelli M, Expression of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex correlates with the macroscopic appearance of early gastric cancer. J Pathol 192(4): 433-9, 2000.
106. Iademarco MF, Barks JL, and Dean DC, Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. J Clin Invest 95(1): 264-71, 1995.
107. Kumar A, Dhawan S, Hardegen NJ, and Aggarwal BB, Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 55(6): 775-83, 1998.
108. Gupta B and Ghosh B, Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 21(11): 745-57, 1999.
109. Jaiswal AS, Marlow BP, Gupta N, and Narayan S, Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)- induced growth arrest and apoptosis in colon cancer cells. Oncogene 21(55): 8414-27, 2002.
110. Anto RJ, Mukhopadhyay A, Denning K, and Aggarwal BB, Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23(1): 143-50, 2002.
111. Bharti AC, Donato N, Singh S, and Aggarwal BB, Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101(3): 1053-62, 2003.
112. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, and Limtrakul PN, Modulation of P-glycoprotein expression and function by curcumin in multidrugresistant human KB cells. Biochem Pharmacol 64(4): 573-82, 2002.
113. Limtrakul P, Anuchapreeda S, and Buddhasukh D, Modulation of human multidrugresistance MDR-1 gene by natural curcuminoids. BMC Cancer 4: 13, 2004.
114. Kapoor ID, Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton, FL, 1990.
115. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, and Kuttan R, Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94(1): 79-83, 1995.
116. Vopel G, Gaisbaver M, and Winklev W, Phytotherapic in der Praxis. Deutschev Arzteverlag 74, 1990.
117. Kottke MK, Scientific and regulatory aspects of nutraceutical products in the United States. Drug Dev Ind Pharm 24(12): 1177-95, 1998.
118. Commandeur JN and Vermeulen NP, Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 26(7): 667-80, 1996.
119. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, and Srinivas PS, Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64(4): 353-6, 1998.
120. Groten JP, Butler W, Feron VJ, Kozianowski G, Renwick AG, and Walker R, An analysis of the possibility for health implications of joint actions and interactions between food additives. Regul Toxicol Pharmacol 31(1): 77-91, 2000.
121. Navis I, Sriganth P, and Premalatha B, Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma. Pharmacol Res 39(3): 175-9, 1999.
122. Conney AH, Lou YR, Xie JG, Osawa T, Newmark HL, Liu Y, Chang RL, and Huang MT, Some perspectives on dietary inhibition of carcinogenesis: studies with curcumin and tea. Proc Soc Exp Biol Med 216(2): 234-45, 1997.
123. Khafif A, Schantz SP, Chou TC, Edelstein D, and Sacks PG, Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19(3): 419-24, 1998.
124. Pulla Reddy AC, Sudharshan E, Appu Rao AG, and Lokesh BR, Interaction of curcumin with human serum albumin-a spectroscopic study. Lipids 34(10): 1025-9, 1999.
125. Jaruga E, Salvioli S, Dobrucki J, Chrul S, Bandorowicz-Pikula J, Sikora E, Franceschi C, Cossarizza A, and Bartosz G, Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett 433(3): 287-93, 1998.
126. Jaruga E, Sokal A, Chrul S, and Bartosz G, Apoptosis-independent alterations in membrane dynamics induced by curcumin. Exp Cell Res 245(2): 303-12, 1998.
127. Pan MH, Huang TM, and Lin JK, Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27(4): 486-94, 1999.
128. Lin JK, Pan MH, and Lin-Shiau SY, Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 13(1-4): 153-8, 2000.
129. Holder GM, Plummer JL, and Ryan AJ, The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8(12): 761-8, 1978.
130. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, and Gescher A, Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3): 1058-64, 2001.
131. Wang F, Yang J, Wu X, and Liu S, Study of the interaction of proteins with curcumin and SDS and its analytical application. Spectrochim Acta A Mol Biomol Spectrosc 61(11-12): 2650-6, 2005.
132. Souza CRA, Osme SF, and Gloria MBA, Stability of curcuminoid pigments in model systems. J Food Processing Preservation 21(5): 353-63, 1997.
133. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, and Hsieh CY, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B): 2895-900, 2001.
134. Holt PR, Katz S, and Kirshoff R, Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50(11): 2191-3, 2005.
135. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, and Steward WP, Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10(20): 6847-54, 2004.
136. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, and Gescher AJ, Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14(1): 120-5, 2005.
137. du Toit LC, Pillay V, and Danckwerts MP, Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 7(1): 118, 2006.
138. Atal CK, Dubey RK, and Singh J, Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 232(1): 258-62, 1985.
139. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, and Fromm MF, Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302(2): 645-50, 2002.
140. Reen RK, Jamwal DS, Taneja SC, Koul JL, Dubey RK, Wiebel FJ, and Singh J, Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochem Pharmacol 46(2): 229-38, 1993.
141. Li L, Braiteh FS, and Kurzrock R, Liposome-encapsulated curcumin. Cancer 104(6): 1322-31, 2005.
142. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, and Gescher AJ, Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol, 60(2): 171-77, 2006.
143. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, and Lehr CM, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299(2): 775-81, 2001.
144. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, and Ravi Kumar MN, Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target 14(1): 27-34, 2006.
145. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, and Shoji M, Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 12(14): 3871-83, 2004.
146. Kumar S, Narain U, Tripathi S, and Misra K, Syntheses of curcumin bioconjugates and study of their antibacterial activities against beta-lactamase-producing microorganisms. Bioconjug Chem 12(4): 464-9, 2001.
147. Kumar S, Misra A, Tripathi S, and Misra K, Study on curcumin-oligonucleotide conjugate as a probable anticancer agent: its hybridisation with telomere target sequence 5′-GGGATTGGGATT-3′. Nucleic Acids Res Suppl (1): 137-8, 2001.
148. Kumar S, Shukla V, Misra A, Tripathi S, and Misra K, New curcumin-bioconjugate; synthesis and DNA binding. Indian J Biotechnology 1: 158-63, 2002.
149. Mishra S, Narain U, Mishra R, and Misra K, Design, development and synthesis of mixed bioconjugates of piperic acid-glycine, curcumin-glycine/alanine and curcumin-glycine-piperic acid and their antibacterial and antifungal properties. Bioorg Med Chem 13(5): 1477-86, 2005.
150. Mishra S, Kapoor N, Mubarak Ali A, Pardhasaradhi BV, Kumari AL, Khar A, and Misra K, Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic Biol Med 38(10): 1353-60, 2005.
151. Mishra S, Tripathi S, Mishra R, and Misra K, Synthesis, characterization and antiproliferative activity of a novel anticancer prodrug designed to target telomerase sequence. Indian J Chem 44B(10): 2582-8, 2005.
152. Mishra S, Tripathi S, and Misra K, Antisense upchar, jaiv-saiyugamak [in Hindi]. Bhartiya Vaigayanik Evam Audyogik Anushandhan Patrika 11(1): 44-7, 2003.
153. Mishra S, Narain U, and Misra K, Glycine ke sath piperine-curcumin jaiv saiyugamak ki sanrachana, abhikalpana anuprayog [in Hindi]. Bhartiya Vaigayanik Evam Audyogik Anushandhan Patrika 11(1): 34-6, 2003.
154. Kapoor N and Misra K, Kuchh navinikreet chakriya yaugikon ki sanrachnatmak, sanshleshnatmak, pratioxikarak prakriya evam fafundinashak guno ka adhayan. Bhartiya vaigyanik evam audthyogik anushandhan patrika 12: 84-5, 2004.
155. Kapoor N, Narain U, Dwivedi V, and Misra K, Bio-active conjugates of curcumin having ester, peptide, thiol and sisulfide links. J Sci Indust Res 66(8): 647-50, 2007.
156. Kapoor N, Sharma A, Dwivedi V, Kumar A, Pati U, and Misra K, Telomerase targeted anticancer bioactive prodrug by antisense-based approach. Cancer Lett 248(2): 245-50.
157. Tamvakopoulos C, Dimas K, Sofianos ZD, Han Z, Wyche JH, and Pantazis P, The curcumin analogue, dimethoxy curcumin: metabolism in liver microsomes, apoptosis induction and stability in cultured human colon cancer cells. Clin Cancer Res 13(4): 1269-77, 2007.
158. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang HK, Itokawa H, Su CY, Shih C, Chiang T, Chang E, Lee Y, Tsai MY, Chang C, and Lee KH, Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 45(23): 5037-42, 2002.
159. Chattopadhyay I, Biswas K, Bandyopadhyay U, and Banerjee RK, Turmeric and curcumin: biological actions and medicinal applications. Current Sci 67(1): 44-53, 2004.
160. Mukhopadhyay A, Basu N, Ghatak N, and Gujral PK, Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12(4): 508-15, 1982.
161. Ghatak N and Basu N, Sodium curcuminate as an effective anti-inflammatory agent. Indian J Exp Biol 10(3): 235-6, 1972.
162. Kumar S, Dubey KK, Tripathi S, Fujii M, and Misra K, Design and synthesis of curcumin-bioconjugates to improve systemic delivery. Nucleic Acids Symp Ser (44): 75-6, 2000.
163. Selvam C, Jachak SM, Thilagavathi R, and Chakraborti AK, Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett 15(7): 1793-7, 2005.
164. Sabinsa Corporation, http://www.tetrahydrocurcuminoids.com/cosmetic.html.
165. Lin L, Shi Q, Nyarko AK, Bastow KF, Wu CC, Su CY, Shih CC, and Lee KH, Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem 49(13): 3963-72, 2006.
166. Sun A, Shoji M, Lu YJ, Liotta DC, and Snyder JP, Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 49(11): 3153-8, 2006.
167. Furness MS, Robinson TP, Ehlers T, Hubbard RB, Arbiser JL, Goldsmith DJ, and Bowen JP, Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des 11(3): 357-73, 2005.
168. Unnikrishnan MK and Rao MN, Inhibition of nitrite induced oxidation of hemoglobin by curcuminoids. Pharmazie 50(7): 490-2, 1995.